RAGE and soluble RAGE: Potential therapeutic targets for cardiovascular diseases

Molecular Medicine

Volumn 13, Issue 11-12, 2007, Pages 625-635

  Koyama, Hidenori ^a   Yamamoto, Hiroshi ^b   Nishizawa, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ROSIGLITAZONE; SULFONYLUREA;

ARTERY INJURY; ATHEROSCLEROSIS; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CELL SURFACE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFLAMMATORY CELL; METABOLIC DISORDER; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SIGNAL TRANSDUCTION;

CARDIOVASCULAR DISEASES; HUMANS; RECEPTORS, IMMUNOLOGIC; SOLUBILITY;

EID: 36849085490     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2007-00087.Koyama     Document Type: Review

References (90)

1. Schmidt AM, Vranna M, Gerlach M, et al. (1992) Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 267:14987-97.
2. Neeper M, Schmidt AM, Brett J, et al. (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267:14998-15004.
3. Kislinger T, Fu C, Huber B, et al. (1999) N(epsilon)-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274:31740-9.
4. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. (1995) N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34:10872-8.
5. Hofmann MA, Drury S, Fu C, et al. (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889-901.
6. Hori O, Brett J, Slattery T, et al. (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin: mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270:25752-61.
7. Taguchi A, Blood DC, del Toro G, et al. (2000) Blockade of RAGE-amphoterin signaling suppresses tumor growth and metastases. Nature 405:354-60.
8. Yan SD, Chen X, Fu J, et al. (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382:685-91.
9. Sousa MM, Yan SD, Stern D, Saraiva MJ. (2000) Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab. Invest. 80:1101-10.
10. Chavakis T, Bierhaus A, Al-Fakhri N, et al. (2003) The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med. 198:1507-15.
11. Krieger M, Stern DM. (2001) Series introduction: multiligand receptors and human disease. J. Clin. Invest. 108:645-7.
12. Schmidt AM, Yan SD, Yan SF, Stern DM. (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 108:949-55.
13. Schmidt AM, Hori O, Chen JX, et al. (1995) Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 96:1395-1403.
14. Basta G, Lazzerini G, Massaro M, et al. (2002) Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105:816-22.
15. Cipollone F, Iezzi A, Fazia M, et al. (2003) The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108:1070-7.
16. Burke AP, Kolodgie FD, Zieske A, et al. (2004) Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler. Thromb. Vasc. Biol. 24:1266-71.
17. Park L, Raman KG, Lee KJ, et al. (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end-products. Nat. Med. 4:1025-031.
18. Kislinger T, Tanji N, Wendt T, et al. (2001) Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 21:905-10.
19. Wendt T, Harja E, Bucciarelli L, et al. (2006) RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 185:70-7.
20. Bucciarelli LG, Wendt T, Ou W, et al. (2002) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106:2827-35.
21. Mizutani M, Kern TS, Lorenzi M. (1996) Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J. Clin. Invest. 97:2883-90.
22. Stitt A, Gardiner TA, Anderson NL, et al. (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51:2826-32.
23. Hammes HP, Du X, Edelstein D, et al. (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 9:294-9.
24. Abaci A, Oguzhan A, Kahraman S, et al. (1999) Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 99:2239-12.
25. Rivard A, Silver M, Chen D, et al. (1999) Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF Am. J. Pathol. 154:355-63.
26. Waltenberger J. (2001) Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc. Res. 49:554-60.
27. Stitt AW, McGoldrick C, Rice-McCaldin A, et al. (2005) Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3. Diabetes 54:785-94.
28. Goova MT, Li J, Kislinger T, et al. (2001) Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am. J. Pathol. 159:513-25.
29. Tamarat R, Silvestre JS, Huijberts M, et al. (2003) Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice. Proc. Nat.l. Acad. Sci. U S A 100:8555-60.
30. Shoji T, Koyama H, Morioka T, et al. (2006) Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes 55:2245-55.
31. Rozenman Y, Sapoznikov D, Mosseri M, et al. (1997) Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of the BARI study: Balloon Angioplasty Revascularization Investigation. J. Am. Coll. Cardiol. 30:1420-5.
32. Abizaid A, Kornowski R, Mintz GS, et al. (1998) The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J. Am. Coll. Cardiol. 32:584-9.
33. Zhou Z, Wang K, Penn MS, et al. (2003) Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 107:2238-43.
34. Sakaguchi T, Yan SF, Yan SD, et al. (2003) Central role of RAGE-dependent neointimal expansion in arterial restenosis. J. Clin. Invest. 111:959-72.
35. Ross R. (1999) Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:115-26.
36. Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. (1993) Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J. Clin. Invest. 91:2155-68.
37. Shanmugam N, Kim YS, Lanting L, Natarajan R. (2003) Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J. Biol. Chem. 278:34834-44.
38. Rouhiainen A, Kuja-Panula J, Wilkman E, et al. (2004) Regulation of monocyte migration by amphoterin (HMGB1). Blood 104:1174-82.
39. Yan SS, Wu ZY, Zhang HP, et al. (2003) Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat. Med. 9:287-93.
40. Chen Y, Yan SD, Colgan J, et al. (2004) Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J. Immunol. 173:1399-1405.
41. Moser B, Szabolcs MJ, Ankersmit HJ, et al. (2007) Blockade of RAGE suppresses alloimmune reactions in vitro and delays allograft rejection in murine heart transplantation. Am. J. Transplant. 7:293-302.
42. Tian J, Avalos AM, Mao SY, et al. (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8:487-96.
43. Orlova VV, Choi EY, Xie C, et al. (2007) A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. Embo. J. 26:1129-39.
44. Malherbe P, Richards JG, Gaillard H, et al. (1999) cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res. Mol. Brain Res. 71:159-70.
45. Yonekura H, Yamamoto Y, Sakurai S, et al. (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 370:1097-109.
46. Schlueter C, Hauke S, Flohr AM, Rogalla P, Bullerdiek J. (2003) Tissue-specific expression patterns of the RAGE receptor and its soluble forms: a result of regulated alternative splicing? Biochim. Biophys. Acta. 1630:1-6.
47. Park IH, Yeon SI, Youn JH, et al. (2004) Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol. Immunol. 40:1203-11.
48. Ding Q, Keller JN. (2005) Splice variants of the receptor for advanced glycosylation end products (RAGE) in human brain. Neurosci. Lett. 373:67-72.
49. Bierhaus A, Humpert PM, Morcos M, et al. (2005) Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 83:876-86.
50. Hudson BI, Harja E, Moser B, Schmidt AM. (2005) Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein? Arterioscter. Thromb. Vasc. Biol. 25:879-82.
51. Hartford LE, Enghild JJ, Valnickova Z, et al. (2004) Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J. Biol. Chem. 279:50019-24.
52. Pullerits R, Brisslert M, Jonsson IM, Tarkowski A. (2006) Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum. 54:3898-907.
53. Falcone C, Emanuele E, D'Angelo A, et al. (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler. Thromb. Vasc. Biol. 25:1032-7.
54. Emanuele E, D'Angelo A, Tomaino C, et al. (2005) Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch. Neurol. 62:1734-6.
55. Sakurai S, Yamamoto Y, Tamei H, et al. (2006) Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res. Clin. Tract. 73:158-65.
56. Koyama H, Shoji T, Yokoyama H, et al. (2005) Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25:2587-93.
57. Humpert PM, Djuric Z, Kopf S, et al. (2007) Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc. Diabetol. 6:9.
58. Katakami N, Matsuhisa M, Kaneto H, et al. (2005) Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 28:2716-21.
59. Katakami N, Matsuhisa M, Kaneto H, Yamasaki Y. (2007) Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patients. Atherosclerosis 190:22-3.
60. Yamagishi S, Adachi H, Nakamura K, et al. (2006) Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 55:1227-31.
61. Miura J, Yamamoto Y, Osawa M, et al. (2007) Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes. Arterioscler. Thromb. Vasc. Biol. 27:253-4.
62. Koyama H, Shoji T, Fukumoto S, et al. (2007) Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler. Thromb. Vasc. Biol. 27:147-53.
63. Geroldi D, Falcone C, Emanuele E, et al. (2005) Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J. Hypertens. 23:1725-9.
64. Basta G, Sironi AM, Lazzerini G, et al. (2006) Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J. Clin. Endocrinol. Metab. 91:4628-34.
65. Devangelio E, Santilli F, Formoso G, et al. (2007) Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic. Biol. Med. 43:511-8.
66. Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL. (2005) Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin. Chem. 51:1749-50.
67. Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ. (2006) Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 49:2756-62.
68. Nakamura K, Yamagishi SI, Adachi H, et al. (2007) Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab. Res. Rev. 23:368-71.
69. Yamamoto Y, Miura J, Sakurai S, et al. (2007) Assaying soluble forms of receptor for advanced glycation end products. Arterioscler. Thromb. Vasc. Biol. 27:e33-4.
70. Humpert PM, Kopf S, Djuric Z, et al. (2006) Plasma sRAGE is independently associated with urinary albumin excretion in type 2 diabetes. Diabetes Care 29:1111-3.
71. Hou FF, Ren H, Owen WF Jr, et al. (2004) Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J. Am. Soc. Nephrol. 15:1889-96.
72. Kalousova M, Hodkova M, Kazderova M, et al. (2006) Soluble receptor for advanced glycation end products in patients with decreased renal function. Am. J Kidney Dis. 47:406-11.
73. Kalousova M, Bartosova K, Zima T, Skibova J, Teplan V, Viklicky O. (2007) Pregnancy-associated plasma protein a and soluble receptor for advanced glycation end products after kidney transplantation. Kidney Blood Press. Res. 30:31-7.
74. Kosaki A, Hasegawa T, Kimura T, et al. (2004) Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 89:5423-8.
75. Wendt TM, Tanji N, Guo J, et al. (2003) RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 162:1123-37.
76. Bierhaus A, Haslbeck KM, Humpert PM, et al. (2004) Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J. Clin. Invest. 114:1741-51.
77. Arancio O, Zhang HP, Chen X, et al. (2004) RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. Embo. J. 23:4096-105.
78. Cheng C, Tsuneyama K, Kominami R, et al. (2005) Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod. Pathol. 18:1385-96.
79. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. (2000) The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J. Biol. Chem. 275:25781-90.
80. Coughlan MT, Thallas-Bonke V, Pete J, et al. (2007) Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology 148:886-95.
81. Zhong Y, Li SH, Liu SM, et al. (2006) C-Reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells. Hypertension 48:504-11.
82. Geroldi D, Falcone C, Minoretti P, Emanuele E, Arra M, D'Angelo A. (2006) High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. J. Am. Geriatr. Soc. 54:1149-50.
83. Forbes JM, Thorpe SR, Thallas-Bonke V, et al. (2005) Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 16:2363-72.
84. Marx N, Walcher D, Ivanova N, et al. (2004) Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 53:2662-8.
85. Okamoto T, Yamagishi S, Inagaki Y, et al. (2002) Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J. 16:1928-30.
86. Cuccurullo C, Iezzi A, Fazia ML, et al. (2006) Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 26:2716-23.
87. Tan KC, Chow WS, Tso AW, et al. (2007) Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia 50:1819-25.
88. Kalousova M, Jachymova M, Mestek O, et al. (2007) Receptor for advanced glycation end products: soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol. Dial. Transplant. 22:2020-6.
89. Nakamura K, Yamagishi S, Adachi H, et al. (2007) Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol. Med. 13:185-9.
90. Nakamura K, Yamagishi SI, Adachi H, et al. (2007) Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab. Res. Rev. Aug 10; [Epub ahead of print].